Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | EDNRA | P25101 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674725 | 0.91 | CA2 (0.45) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL12200891 | 0.79 | CYP1A2 (0.56) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL14569242 | 0.79 | CYP1A2 (0.63) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL11888406 | 0.78 | CYP1A2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1645476 | 0.78 | CA2 (0.52) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL13655537 | 0.78 | HDAC4 (0.56) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL9288054 | 0.77 | CYP1A2 (0.53) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL13598768 | 0.76 | HDAC4 (0.59) | CYP2C19HIF1AF2PRSS1PRSS2 | |
| SCHEMBL20535016 | 0.74 | KMT2A (0.37) | CYP1A2CYP2C19HTTL3MBTL1F2 | |
| SCHEMBL1556328 | 0.74 | F2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233401-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | UNIVERSITY OF MANITOBA (CA) | 2019-08-01 | — | — | US | disclosed |
| EP-3357920-A1 | BIOCIDAL COMPOUNDS AND METHODS FOR USING SAME | Exigence Technologies Inc. (CA) | 2018-08-08 | — | — | EP | disclosed |
| US-20180086740-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | EXIGENCE TECH INC (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20170204085-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | EXIGENCE TECHNOLOGIES INC. (CA) | 2017-07-20 | — | — | US | disclosed |
| US-20150118179-A1 | BIOCIDAL COMPOUNDS AND METHODS FOR USING SAME | UNIVERSITY OF MANITOBA (CA) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233401-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | BCHE, NHERF1, HCN3 | CA2 398/4885CYP1A2 2696/4885CYP2C19 1867/4885 |
| US-20170204085-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | MPO, HNMT, TYR | CA2 690/4885CYP1A2 2416/4885CYP2C19 1326/4885 |
| US-20150118179-A1 | BIOCIDAL COMPOUNDS AND METHODS FOR USING SAME | NQO2, DLAT, TYR | CA2 1145/4885CYP1A2 1607/4885CYP2C19 1214/4885 |
| US-20180086740-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | BCHE, NHERF1, HCN3 | CA2 398/4885CYP1A2 2696/4885CYP2C19 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.